Whole-exome sequencing showed a pathogenic mutation in STAT1 (c.1154C→T, pT385 M) that confirmed the diagnosis of STAT1 gain-of-function disease. 3,4 ...

In patients with type 1 diabetes of recent onset, daily treatment with baricitinib over 48 weeks appeared to preserve β-cell function as estimated by the mixed-meal–stimulated mean C-peptide level.

New England Journal of Medicine Source Reference: Waibel M, et al "Baricitinib and β-cell function in patients with new-onset type 1 diabetes" N Engl J Med 2023; DOI: 10.1056/NEJMoa2306691.